Target Patient Population: Adults >45 years of age, with a body mass index (BMI) of ≥27 kg/m2 and heart related and/or kidney related disease
Study Overview: To evaluate the efficacy and safety of retatrutide versus placebo in reducing the risk for major cardiovascular events.
Study Timeline: Anticipated patient participation is up to 5 years. This study is comprised of both remote and clinic visits.
OTHER: The study coordinator at the practice will provide the practice staff with an overview of the study and the key eligibility criteria for patients that may qualify for participation. We appreciate the practices support with this clinical trial, which may include:
- helping to identify patients,
- ensuring clinical trials materials that are delivered to the office are given to the coordinator, and
- providing support with study procedures such as vitals, labs and medical histories (as applicable and delegated by the Investigator).
Number of Patients Currently Active in the Trial: 1